21 results on '"S Negres"'
Search Results
2. 4CPS-309 Barriers to adherence with prescribed treatments in multiple sclerosis patients
- Author
-
SM Oprea and S Negres
- Subjects
medicine.medical_specialty ,business.industry ,Missed Dose ,Retrospective cohort study ,Disease ,medicine.disease ,Affect (psychology) ,Tolerability ,Internal medicine ,medicine ,Observational study ,Young adult ,business ,Progressive disease - Abstract
Background and importance Multiple sclerosis (MS) is a chronic progressive disease, one of the main causes of invalidity among young adults. Adherence may be difficult because treatment benefits are not immediately apparent, and most disease modifying therapies (DMTs) have tolerability and safety issues. Aim and objectives In our hospital, where almost 800 MS patients are treated monthly, no study has assessed adherence, so the purpose of this study was to evaluate adherence and identify patient reported barriers regarding adherence. Material and methods An observational retrospective study was conducted (January 2017 to January 2019). We evaluated adherence using missed dose ratio (MDR), and identified and quantified barriers to adherence using the MS treatment adherence questionnaire (MSTAQ). This tool has 30 items in three subscales: DMT barriers to adherence, DMT side effects (SE) and DMT coping strategies. We also collected demographic (age, sex) and treatment information (current DMT, DMT history, reason for switch therapy and exposure to treatment). Results 60 patients (44 women), average age 40.47 years had a mean treatment exposure of 6.38 years. Adherence was high because only 11 had missed one or more doses in the last month (MDR >0). When asked about missed dose in general, 22 patients reported barriers to taking medication. DMT scores are described in table 1. Conclusion and relevance Overall, adherence was high even though there were some barriers to adherence. SE and long duration of treatment could affect adherence, which is why it is important to detect and overcome barriers using such questionaries, to identify in time non-adherent patients and counsel them appropriately on how to use more coping strategies. References and/or acknowledgements Conflict of interest No conflict of interest
- Published
- 2021
- Full Text
- View/download PDF
3. 4CPS-308 Experience with teriflunomide treatment for multiple sclerosis in a university hospital
- Author
-
SM Oprea and S Negres
- Subjects
medicine.medical_specialty ,Expanded Disability Status Scale ,business.industry ,Medical record ,Multiple sclerosis ,Retrospective cohort study ,medicine.disease ,chemistry.chemical_compound ,Natalizumab ,chemistry ,Internal medicine ,Teriflunomide ,medicine ,Young adult ,Glatiramer acetate ,business ,medicine.drug - Abstract
Background and importance Teriflunomide (TRF) is a once daily oral immunomodulatory drug approved in over 80 countries for multiple sclerosis (MS). It is indicated in young adults and contraindicated in pregnant women or women of reproductive age because of the potential for fetal harm. TRF became available as a unique option for oral MS treatment in our hospital in 2017. Aim and objectives To describe our experience with the use of TRF and assess its safety profile, as disease modifying therapies (DMTs) work differently and have different adverse reactions (AR). Material and methods An observational retrospective study was conducted from January 2017 to January 2020. Collected variables from medical records were: age, sex, expanded disability status scale score (EDSS), previous DMTs, safety profile (AR, suspension of TRF treatment) and results of blood tests. Sustained disability progression was defined as at least a 1 point increase from the baseline EDSS score ≤5.5 (or at least a 0.5 point increase for those with a baseline EDSS score >5.5) sustained for at least 12 weeks.1 Results 45 patients were analysed, 10 men and 35 women (mean age 35.7 years). TRF was the firstline drug for 10 patients, the rest had switched to TRF from parenteral therapies: 7 subcutaneous glatiramer acetate, 20 intramuscular or subcutaneous interferon beta and 2 intravenous natalizumab. The main reasons for change were: convenience of oral administration, poor tolerance and AR at the site of injection. The average duration for TRF was 2.5 years with no suspension recorded. In this period, for 30 patients EDSS score remained stable. The mean change in EDSS from baseline was 0.7; no increase in disability progression. 30 patients showed no AR and 15 patients presented gastrointestinal disorders (9), temporary alopecia (4) or headache (2). 9 patients experienced moderate elevation of liver enzymes. Conclusion and relevance TRF seemed to have a manageable safety profile, was well tolerated, and no new or unexpected AR were reported and there were no suspensions of treatment. Because our experience reflects only 3 years, increased monitoring is necessary to assess the long term safety. References and/or acknowledgements AUBAGIO (package insert). Cambridge, MA: Genzyme Corporation Conflict of interest No conflict of interest
- Published
- 2021
- Full Text
- View/download PDF
4. 4CPS-137 Natalizumab: a review of its use in the management of multiple sclerosis, experience in a university hospital
- Author
-
S Negres and S Oprea
- Subjects
Pediatrics ,medicine.medical_specialty ,Expanded Disability Status Scale ,business.industry ,Incidence (epidemiology) ,Medical record ,Multiple sclerosis ,Retrospective cohort study ,Management of multiple sclerosis ,medicine.disease ,Natalizumab ,Ambulatory ,medicine ,business ,medicine.drug - Abstract
Background Natalizumab is the first licensed treatment, given by infusion, monthly, for highly active relapsing-remitting multiple sclerosis or rapidly evolving severe MS. It is not a cure, its safety issues represent a relevant limitation and impose strict clinical surveillance mainly because of the risk of progressive multi-focal leukoencephalopathy (PML), (a potentially lethal brain disorder. Purpose Review of use: effectiveness, safety, reason for start or switch. Material and methods Retrospective observational study 2015–2018. Treatment history, demographic and clinical data were collected from medical records We assessed effectiveness by the change in expanded disability status scale (EDSS), defined by Fernandez et al: improvement, a decrease of ≥1 point, stability, a change of Safety was assessed by analysing the incidence of adverse reactions and risk for PML stratified in high, medium and low based on three major risk factors: duration of treatment >2 years, prior immunosuppressive treatment and positive serum JC virus antibodies. Results Fifty-six patients, 57% female, mean age at diagnosis 26.4. Eleven patients received Natalizumab as first option and 45 were switched because of lack of efficacy with one or two immunomodulatory drugs prior to Natalizumab. Most patients were still ambulatory when they began treatment (median EDSS 2.00). Mean treatment duration was 3.3 years (1–10 years). Over the study period, the age of starting natalizumab has decreased and the total number of treated patients has increased from 31 to 56. Natalizumab was generally well tolerated, as only four left for the reason of inefficacy and one for PML. Stabilisation of EDSS was achieved for 70% of patients:; only 10% showed worsening. Forty patients showed no risk for PML ( Ninety-three per cent had relapsed at least once in the year prior to natalizumab and 12 months after, the proportion decreased to 15%. Conclusion Natalizumab provides efficacy in slowing disease progression and reducing relapses, effective particularly in patients with less disability and without prior treatment. As long as the risk of PML is managed effectively and patients are constantly informed about their benefit-risk level, it remains a valuable therapeutic option. References and/or acknowledgements No conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
5. 4CPS-138 Quality of life in multiple sclerosis patients with parenteral first-line treatment: experience in a university hospital
- Author
-
S Negres and S Oprea
- Subjects
medicine.medical_specialty ,business.industry ,Medical record ,Neurological disorder ,medicine.disease ,Mental health ,Quality of life ,Health care ,medicine ,Physical therapy ,Anxiety ,medicine.symptom ,business ,Psychosocial ,Depression (differential diagnoses) ,Section 4: Clinical pharmacy services - Abstract
Background Multiple sclerosis (MS), a neurological disorder, demands personalised drug treatment. Parenteral first-line treatment for MS include disease-modifying therapies: intramuscular (IM) interferon (IFN) beta-1a, subcutaneous (SC) IFN-beta 1-a, IFN-beta 1-b and glatiramer acetate. Patients may respond well, ‘look fine’ but have a reduced quality of life (QoL). Purpose To assess the relationship between biological variables (age, EDSS, duration of drug use), QoL and neuropsychiatric complications, aware that the overall wellbeing of patients is not a simple manifestation of impairment or disability but also of many psychosocial and emotional factors. Material and methods Retrospective study, January 2016 to September 2017,patients with chronic treatment for years. Data collected from the patients’ medical records. The instrument used was the Multiple Sclerosis Quality of Life-54 questionnaire with two major components: physical health and mental health. An Excel database was designed to analyse the results. Results Fifty-five patients, mean age 41.2 (24–64) with a median of MS-7 years. Eleven with GA, 44 with INF. forty-three (78%) were females. The average number of patient’ visits to the Neurology Department during the last year was three. We established two categories of patients: The young group (24–35) years respond well to treatment, EDSS 0–1, free of significant physical symptoms, but QoL is seriously impaired. In these patients the scores from the questionnaire show that their physical health is much better than their mental health. Negative relationship between age, mental symptoms and QoL. Over 35 years, with neurological dysfunction, EDSS>3.5, view their QoL in a positive light, continue to participate fully in life, mental health better than physical health, with positive correlations of QoL with age and mental symptoms despite their neurological disability. There were significant differences in QoL based on age and duration of drug use. Significant differences in mental and physical health occur at extreme ages of patients (24–64), young patients present with mental health affected by poor QoL, due to factors such as depression, anxiety and stress. Conclusion Is important to assess QoL in MS patients, not common in every clinical practice, from the beginning, during the routine clinical visits to identify those patients most in need of pharmaceutical care. Physical and mental health aspects of lives should be screened for carefully. The role of healthcare clinicians should be in education and counselling to improve QoL. No conflict of interest
- Published
- 2018
6. Appraisal Of The Knowledge And Behaviors Of Hypertensive Patients To Self-Management Of Hypertension – A Qualitative Study In The Community Pharmacy
- Author
-
Valentina Buda, Maria Suciu, Lavinia Vlaia, S. Negres, Mirela Voicu, Vicentiu Vlaia, C.M. Mabda, Minodora Andor, L. Suciu, L. Dragan, and Carmen Cristescu
- Subjects
Self-management ,Nursing ,Community pharmacy ,Cardiology and Cardiovascular Medicine ,Psychology ,Qualitative research - Published
- 2019
- Full Text
- View/download PDF
7. Exploring the knowledge, the reasons and the prevalence of the contraindicated use of combined oral contraceptives
- Author
-
Mirela Voicu, Vicentiu Vlaia, L. Suciu, Maria Suciu, Carmen Cristescu, Minodora Andor, C.M. Mabda, Valentina Buda, L. Dragan, S. Negres, and Lavinia Vlaia
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,medicine ,Combined oral contraceptives ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
- Full Text
- View/download PDF
8. Knowledge, attitudes and practices on self-monitoring blood pressure and blood glucose level in patients with arterial hypertension and type II diabetes mellitus
- Author
-
Lavinia Vlaia, Carmen Cristescu, Minodora Andor, S. Negres, Vicentiu Vlaia, and Maria Suciu
- Subjects
Type ii diabetes ,medicine.medical_specialty ,Blood pressure ,business.industry ,Internal medicine ,medicine ,Self-monitoring ,Cardiology ,In patient ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
- Full Text
- View/download PDF
9. Research on the antidepressant effect of the association hyperforin–sertraline
- Author
-
C.E. Zbarcea, C.I. Mesarus, C. Chirita, V. Gonciar, S. Negres, A. Zanfirescu, C. Scutari, and O.T. Olaru
- Subjects
Pharmacology ,Sertraline ,business.industry ,Psychiatry and Mental health ,Hyperforin ,chemistry.chemical_compound ,Neurology ,chemistry ,medicine ,Antidepressant ,Pharmacology (medical) ,Neurology (clinical) ,business ,Biological Psychiatry ,medicine.drug - Published
- 2016
- Full Text
- View/download PDF
10. The double-way effects of naloxone and clonidine on experimental stress analgesia
- Author
-
A, Cristea, S, Negres, and D, Joean
- Subjects
Male ,Mice ,Dose-Response Relationship, Drug ,Naloxone ,Stress, Physiological ,Narcotic Antagonists ,Sympatholytics ,Animals ,Analgesia ,Clonidine - Abstract
We have emitted the hypothesis that the double-way effect is possible not only due to the wide range of receptor substrates and receptor subtypes but it can manifest at the heterosynaptic and synaptic cotransmission level as a consequence of the informational unbalance which very low or very high doses of biological signals (in pathological disorders) or of drug signal (agonist or antagonist) can do on physiological balance between both two coupled synaptic systems. To verify this hypothesis we choosed as place of manifesting and observing of the phenomen the informational gearing between the endogenous opioid system as "modulator" and the catecholaminergic systems as "alarm". As drug signals we used naloxone (NALX) and clonidine (CLON). The function studied to reveal the double-way effect was stress analgesia monitored in the classical test of te "hot plate". The experimental stress was induced to the mouse by submitting to forced swimming using the "despair test". In the work are presented the dose-effect curves and inflexion points which mark the changing of the sense of the effect.
- Published
- 1995
11. Identification, analysis and prediction of valid and false information related to vaccines from Romanian tweets.
- Author
-
Valeanu A, Mihai DP, Andrei C, Puscasu C, Ionica AM, Hinoveanu MI, Predoi VP, Bulancea E, Chirita C, Negres S, and Marineci CD
- Subjects
- Humans, Romania, Language, Algorithms, Communication, Vaccines
- Abstract
Introduction: The online misinformation might undermine the vaccination efforts. Therefore, given the fact that no study specifically analyzed online vaccine related content written in Romanian, the main objective of the study was to detect and evaluate tweets related to vaccines and written in Romanian language., Methods: 1,400 Romanian vaccine related tweets were manually classified in true, neutral and fake information and analyzed based on wordcloud representations, a correlation analysis between the three classes and specific tweet characteristics and the validation of several predictive machine learning algorithms., Results and Discussion: The tweets annotated as misinformation showed specific word patterns and were liked and reshared more often as compared to the true and neutral ones. The validation of the machine learning algorithms yielded enhanced results in terms of Area Under the Receiver Operating Characteristic Curve Score (0.744-0.843) when evaluating the Support Vector Classifier. The predictive model estimates in a well calibrated manner the probability that a specific Twitter post is true, neutral or fake. The current study offers important insights regarding vaccine related online content written in an Eastern European language. Future studies must aim at building an online platform for rapid identification of vaccine misinformation and raising awareness for the general population., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Valeanu, Mihai, Andrei, Puscasu, Ionica, Hinoveanu, Predoi, Bulancea, Chirita, Negres and Marineci.)
- Published
- 2024
- Full Text
- View/download PDF
12. Switching Rat Resident Macrophages from M1 to M2 Phenotype by Iba1 Silencing Has Analgesic Effects in SNL-Induced Neuropathic Pain.
- Author
-
Gheorghe RO, Grosu AV, Magercu M, Ghenghea MS, Zbarcea CE, Tanase A, Negres S, Filippi A, Chiritoiu G, Gherghiceanu M, Dinescu S, Gaina G, Sapunar D, and Ristoiu V
- Subjects
- Animals, Rats, Analgesics pharmacology, Anti-Inflammatory Agents pharmacology, Ganglia, Spinal metabolism, Hyperalgesia metabolism, Macrophages metabolism, Spinal Nerves metabolism, Neuralgia genetics, Neuralgia therapy
- Abstract
Resident macrophages from dorsal root ganglia are important for the development of traumatic-induced neuropathic pain. In the first 5-7 days after a traumatic sciatic nerve injury (i.e., spinal nerve ligation (SNL), spared nerve injury (SNI), sciatic nerve transection or sciatic nerve ligation and transection), Ionized binding adapter protein 1 (Iba1) (+) resident macrophages cluster around dorsal root ganglia neurons, possibly contributing to nerve injury-induced hypersensitivity. Since infiltrating macrophages gradually recruited to the lesion site peak at about 7 days, the first few days post-lesion offer a window of opportunity when the contribution of Iba1 (+) resident macrophages to neuropathic pain pathogenesis could be investigated. Iba1 is an actin cross-linking cytoskeleton protein, specifically located only in macrophages and microglia. In this study, we explored the contribution of rat Iba1 (+) macrophages in SNL-induced neuropathic pain by using intra-ganglionic injections of naked Iba1-siRNA, delivered at the time the lesion occurred. The results show that 5 days after Iba1 silencing, Iba1 (+) resident macrophages are switched from an M1 (pro-inflammatory) phenotype to an M2 (anti-inflammatory) phenotype, which was confirmed by a significant decrease of M1 markers (CD32 and CD86), a significant increase of M2 markers (CD163 and Arginase-1), a reduced secretion of pro-inflammatory cytokines (IL-6, TNF-α and IL-1β) and an increased release of pro-regenerative factors (BDNF, NGF and NT-3) which initiated the regrowth of adult DRG neurites and reduced SNL-induced neuropathic pain. Our data show for the first time, that it is possible to induce macrophages towards an anti-inflammatory phenotype by interacting with their cytoskeleton.
- Published
- 2023
- Full Text
- View/download PDF
13. In Silico Drug Repurposing Framework Predicts Repaglinide, Agomelatine and Protokylol as TRPV1 Modulators with Analgesic Activity.
- Author
-
Andrei C, Mihai DP, Zanfirescu A, Nitulescu GM, and Negres S
- Abstract
Pain is one of the most common symptoms experienced by patients. The use of current analgesics is limited by low efficacy and important side effects. Transient receptor potential vanilloid-1 (TRPV1) is a non-selective cation channel, activated by capsaicin, heat, low pH or pro-inflammatory agents. Since TRPV1 is a potential target for the development of novel analgesics due to its distribution and function, we aimed to develop an in silico drug repositioning framework to predict potential TRPV1 ligands among approved drugs as candidates for treating various types of pain. Structures of known TRPV1 agonists and antagonists were retrieved from ChEMBL databases and three datasets were established: agonists, antagonists and inactive molecules (pIC50 or pEC50 < 5 M). Structures of candidates for repurposing were retrieved from the DrugBank database. The curated active/inactive datasets were used to build and validate ligand-based predictive models using Bemis−Murcko structural scaffolds, plain ring systems, flexophore similarities and molecular descriptors. Further, molecular docking studies were performed on both active and inactive conformations of the TRPV1 channel to predict the binding affinities of repurposing candidates. Variables obtained from calculated scaffold-based activity scores, molecular descriptors criteria and molecular docking were used to build a multi-class neural network as an integrated machine learning algorithm to predict TRPV1 antagonists and agonists. The proposed predictive model had a higher accuracy for classifying TRPV1 agonists than antagonists, the ROC AUC values being 0.980 for predicting agonists, 0.972 for antagonists and 0.952 for inactive molecules. After screening the approved drugs with the validated algorithm, repaglinide (antidiabetic) and agomelatine (antidepressant) emerged as potential TRPV1 antagonists, and protokylol (bronchodilator) as an agonist. Further studies are required to confirm the predicted activity on TRPV1 and to assess the candidates’ efficacy in alleviating pain.
- Published
- 2022
- Full Text
- View/download PDF
14. An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure.
- Author
-
Buda V, Prelipcean A, Cozma D, Man DE, Negres S, Scurtu A, Suciu M, Andor M, Danciu C, Crisan S, Dehelean CA, Petrescu L, and Rachieru C
- Abstract
Since the prevalence of heart failure (HF) increases with age, HF is now one of the most common reasons for the hospitalization of elderly people. Although the treatment strategies and overall outcomes of HF patients have improved over time, hospitalization and mortality rates remain elevated, especially in developed countries where populations are aging. Therefore, this paper is intended to be a valuable multidisciplinary source of information for both doctors (cardiologists and general physicians) and pharmacists in order to decrease the morbidity and mortality of heart failure patients. We address several aspects regarding pharmacological treatment (including new approaches in HF treatment strategies [sacubitril/valsartan combination and sodium glucose co-transporter-2 inhibitors]), as well as the particularities of patients (age-induced changes and sex differences) and treatment (pharmacokinetic and pharmacodynamic changes in drugs; cardiorenal syndrome). The article also highlights several drugs and food supplements that may worsen the prognosis of HF patients and discusses some potential drug-drug interactions, their consequences and recommendations for health care providers, as well as the risks of adverse drug reactions and treatment discontinuation, as an interdisciplinary approach to treatment is essential for HF patients.
- Published
- 2022
- Full Text
- View/download PDF
15. Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress.
- Author
-
Mihai DP, Ungurianu A, Ciotu CI, Fischer MJM, Olaru OT, Nitulescu GM, Andrei C, Zbarcea CE, Zanfirescu A, Seremet OC, Chirita C, and Negres S
- Subjects
- Animals, Corpus Callosum drug effects, Cuprizone, Disease Models, Animal, Drug Evaluation, Preclinical, Febuxostat pharmacology, Female, HEK293 Cells, Humans, Mice, Inbred C57BL, Motor Activity drug effects, Neurotransmitter Agents pharmacology, Risperidone pharmacology, TRPA1 Cation Channel drug effects, Venlafaxine Hydrochloride pharmacology, Mice, Febuxostat therapeutic use, Multiple Sclerosis drug therapy, Neurotransmitter Agents therapeutic use, Risperidone therapeutic use, Venlafaxine Hydrochloride therapeutic use
- Abstract
Multiple sclerosis (MS) is a demyelinating, autoimmune disease that affects a large number of young adults. Novel therapies for MS are needed considering the efficiency and safety limitations of current treatments. In our study, we investigated the effects of venlafaxine (antidepressant, serotonin-norepinephrine reuptake inhibitor), risperidone (atypical antipsychotic) and febuxostat (gout medication, xanthine oxidase inhibitor) in the cuprizone mouse model of acute demyelination, hypothesizing an antagonistic effect on TRPA1 calcium channels. Cuprizone and drugs were administered to C57BL6/J mice for five weeks and locomotor activity, motor performance and cold sensitivity were assessed. Mice brains were harvested for histological staining and assessment of oxidative stress markers. Febuxostat and metabolites of venlafaxine (desvenlafaxine) and risperidone (paliperidone) were tested for TRPA1 antagonistic activity. Following treatment, venlafaxine and risperidone significantly improved motor performance and sensitivity to a cold stimulus. All administered drugs ameliorated the cuprizone-induced deficit of superoxide dismutase activity. Desvenlafaxine and paliperidone showed no activity on TRPA1, while febuxostat exhibited agonistic activity at high concentrations. Our findings indicated that all three drugs offered some protection against the effects of cuprizone-induced demyelination. The agonistic activity of febuxostat can be of potential use for discovering novel TRPA1 ligands.
- Published
- 2021
- Full Text
- View/download PDF
16. Author Correction: The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy.
- Author
-
Valeanu A, Damian C, Marineci CD, and Negres S
- Published
- 2021
- Full Text
- View/download PDF
17. The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy.
- Author
-
Valeanu A, Damian C, Marineci CD, and Negres S
- Subjects
- Aged, 80 and over, Algorithms, Comorbidity, Hospitalization statistics & numerical data, Humans, Male, ROC Curve, Risk Factors, Adverse Drug Reaction Reporting Systems statistics & numerical data, Drug-Related Side Effects and Adverse Reactions prevention & control, Polypharmacy
- Abstract
Only few applications are currently dealing with personalized adverse drug reactions (ADRs) prediction in case of polypharmacy. The study aimed to develop a patient-tailored ADR web application, considering characteristics from 734 drugs and relevant patient related factors. The application was designed in Python using a scoring and ranking system based on frequency and severity, computed for each ADR and expressed through an online platform. A neural networks algorithm was used for predicting the severity of ADRs. The application inputs are: age, gender, drugs, relevant pathologies. The outputs are: an overall severity profile (hospitalization and mortality risk), a stratified risk on specific ADR groups and a sorted list of the most important ADRs depending on frequency and severity. The Severity prediction model validation resulted in 79.7-85.1% Area Under the Receiver Operating Characteristic Curve Score, which lies in the good cut-off of 75-90%. The program offers a complex view regarding the ADR profile of a given patient and could be used by the physician and clinical pharmacist during patient safety monitoring, for a coherent therapy choice or medication adjustment, due to the good therapy coverage and the inclusion of relevant patient comorbidities.
- Published
- 2020
- Full Text
- View/download PDF
18. Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.
- Author
-
Mihai DP, Nitulescu GM, Ion GND, Ciotu CI, Chirita C, and Negres S
- Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS) through neurodegeneration and demyelination, leading to physical/cognitive disability and neurological defects. A viable target for treating MS appears to be the Transient Receptor Potential Ankyrin 1 (TRPA1) calcium channel, whose inhibition has been shown to have beneficial effects on neuroglial cells and protect against demyelination. Using computational drug discovery and data mining methods, we performed an in silico screening study combining chemical graph mining, quantitative structure-activity relationship (QSAR) modeling, and molecular docking techniques in a global prediction model in order to identify repurposable drugs as potent TRPA1 antagonists that may serve as potential treatments for MS patients. After screening the DrugBank database with the combined generated algorithm, 903 repurposable structures were selected, with 97 displaying satisfactory inhibition probabilities and pharmacokinetics. Among the top 10 most probable inhibitors of TRPA1 with good blood brain barrier (BBB) permeability, desvenlafaxine, paliperidone, and febuxostat emerged as the most promising repurposable agents for treating MS. Molecular docking studies indicated that desvenlafaxine, paliperidone, and febuxostat are likely to induce allosteric TRPA1 channel inhibition. Future in vitro and in vivo studies are needed to confirm the biological activity of the selected hit molecules.
- Published
- 2019
- Full Text
- View/download PDF
19. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
- Author
-
Duca G, Pogrebnoi S, Boldescu V, Aksakal F, Uncu A, Valica V, Uncu L, Negres S, Nicolescu F, and Macaev F
- Subjects
- Animals, Bacterial Proteins chemistry, Binding Sites, Male, Mice, Microbial Sensitivity Tests, Models, Molecular, Molecular Docking Simulation, Quinazolines chemistry, Structure-Activity Relationship, Toxicity Tests, Antitubercular Agents chemical synthesis, Antitubercular Agents pharmacology, Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) antagonists & inhibitors, Mycobacterium tuberculosis drug effects
- Abstract
Background: High numbers of infection with resistant forms of Micobacterium tuberculosis (Mtb) contribute to a constant growing demand in new highly active and effective therapeutics. Current drug discovery efforts directed towards new antituberculosis agents include the development of new inhibitors of enoyl-acyl carrier protein reductase (InhA) that do not require activation by the specific enzymes. Tryptanthrin is a known inhibitor of Mtb InhA and its analogues are investigated as potential agents with antimycobacterial efficiency., Objective: The main objective of the presented research was to develop a new group of tryptanthrin analogues with good inhibition properties against Mtb., Methods: Synthesis of new derivatives of 5H-[1,3,4]thiadiazolo[2,3- b]quinazolin-5-one and evaluation of their activity against Mtb, as well as acute and chronic toxicity studies were carried out. Molecular modeling studies were performed to investigate the binding mechanisms of the synthesized ligands with InhA. Binding energies and non-covalent interactions stabilizing the ligand-receptor complexes were obtained from the results of molecular docking., Results: The most active compound in the obtained series, 2-(propylthio)-5H-[1,3,4]thiadiazolo[2,3- b]quinazolin-5-one, exhibited the superior inhibition activity (up to 100%) against mycobacterial growth at MIC 6.5 µg/mL, showed good affinity to the InhA enzyme in docking studies and demonstrated a very low per oral toxicity in animals falling under the category 5 according to GHS classification., Conclusion: 2-(propylthio)-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one can be further explored for the development of a new series of compounds active against Mtb., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2019
- Full Text
- View/download PDF
20. Toxicity of plant extracts containing pyrrolizidine alkaloids using alternative invertebrate models.
- Author
-
Seremet OC, Olaru OT, Gutu CM, Nitulescu GM, Ilie M, Negres S, Zbarcea CE, Purdel CN, Spandidos DA, Tsatsakis AM, Coleman MD, and Margina DM
- Subjects
- Animals, Gas Chromatography-Mass Spectrometry, Inhibitory Concentration 50, Plants, Medicinal chemistry, Toxicity Tests, Invertebrates drug effects, Plant Extracts toxicity, Pyrrolizidine Alkaloids toxicity
- Abstract
Pyrrolizidine alkaloids (PAs) are a widespread class of hepatotoxic heterocyclic organic compounds found in approximately 3% of world flora. Some PAs have been shown to have genotoxic and carcinogenic effects. The present study focuses on the toxicity effects of four dry extracts obtained from medicinal plants (Senecio vernalis, Symphytum officinale, Petasites hybridus and Tussilago farfara), on two aquatic organisms, Artemia salina and Daphnia magna, and the correlation with their PAs content. A new GC‑MS method, using a retention time (TR)‑5MS type capillary column was developed. PAs Kovats retention indices, for this type of column were computed for the first time. The lethal dose 50% (LC50) values for the two invertebrate models were correlated (Pearson 's coefficient, >0.9) and the toxicity was PA concentration-dependent, for three of the four extracts. All tested extracts were found to be toxic in both aquatic organism models. The results can be used to develop a GC‑MS validated method for the assay of PAs in medicinal plants with a further potential application in the risk assessment study of PAs toxicity in humans.
- Published
- 2018
- Full Text
- View/download PDF
21. The double-way effects of naloxone and clonidine on experimental stress analgesia.
- Author
-
Cristea A, Negres S, and Joean D
- Subjects
- Animals, Dose-Response Relationship, Drug, Male, Mice, Stress, Physiological drug therapy, Analgesia, Clonidine pharmacology, Naloxone pharmacology, Narcotic Antagonists pharmacology, Stress, Physiological physiopathology, Sympatholytics pharmacology
- Abstract
We have emitted the hypothesis that the double-way effect is possible not only due to the wide range of receptor substrates and receptor subtypes but it can manifest at the heterosynaptic and synaptic cotransmission level as a consequence of the informational unbalance which very low or very high doses of biological signals (in pathological disorders) or of drug signal (agonist or antagonist) can do on physiological balance between both two coupled synaptic systems. To verify this hypothesis we choosed as place of manifesting and observing of the phenomen the informational gearing between the endogenous opioid system as "modulator" and the catecholaminergic systems as "alarm". As drug signals we used naloxone (NALX) and clonidine (CLON). The function studied to reveal the double-way effect was stress analgesia monitored in the classical test of te "hot plate". The experimental stress was induced to the mouse by submitting to forced swimming using the "despair test". In the work are presented the dose-effect curves and inflexion points which mark the changing of the sense of the effect.
- Published
- 1995
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.